Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
AstraZeneca (United Kingdom) · Melbourn Science Park · +7 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
910
total citations
- FWCI
- 27.92
- Percentile
- 100%
- References
- 76
Citations per year
Authors
5- LKLeila Khoja
AstraZeneca (United Kingdom), Melbourn Science Park, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital
- DDDaphne Day
Ontario Institute for Cancer Research, University of Toronto, Princess Margaret Cancer Centre
- TWTom Wei‐Wu Chen
National Taiwan University, National Taiwan University Hospital
- LSL.L. Siu
University of Toronto, Princess Margaret Cancer Centre
- ARAaron R. HansenCorresponding
University of Toronto, Princess Margaret Cancer Centre
Topics & keywords
Topics
Keywords
- Medicine
- Internal medicine
- Adverse effect
- Rash
- Nivolumab
- Immunology
- Pneumonitis
- Cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.